Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology recommended by NICE. These cookies remember information that ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative devices and digital therapeutics transform patient care as ...

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

NICE has today (10 th June) published final draft guidance which recommends several treatment options for around 25,000 people with moderate rheumatoid arthritis that have not responded to ...

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] Technology appraisal guidance Venetoclax with ibrutinib for treating ...

The appraisal committee sub-group has prepared final draft guidance (FDG) on linzagolix for treating symptoms of endometriosis and submitted it to NICE. The FDG has been sent to consultees for this ...